A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma

Advanced Multiple Myeloma Clinical Trial

Status Completed

Clinical Trial Summary

This is a Phase 2 study during which patients with advanced multiple myeloma will receive either carfilzomib alone (single-agent) or carfilzomib in combination with investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of both single-agent carfilzomib and carfilzomib + filanesib in treating myeloma. Patients will be allowed to crossover from single-agent carfilzomib to carfilzomib + filanesib if disease progression occurs. Approximately 75 patients from the US will be enrolled in this study.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Advanced Multiple Myeloma
• Multiple Myeloma
• Neoplasms, Plasma Cell

• NCT number: NCT01989325
• Study type: Interventional
• Source: Pfizer
• Status: Completed
• Phase: Phase 2
• Start date: November 2013
• Completion date: May 2016